Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prusogliptin + dapagliflozin + metformin in type 2 diabetes mellitus
CTR20252264Phase 3Active
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of prusogliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by CSPC Ouyi Pharmaceutical. Started Jul 2025; status: active.
02
Drugs
prusogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20252264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252264.